Cellares closed a $257 million Series D to scale its automated cell‑therapy manufacturing platform and prepare for a 2027 IPO, accelerating its commercial cell‑therapy production services. The company plans to expand manufacturing footprint and commercial offerings aimed at reducing cost and cycle time for autologous and allogeneic therapies. In related lab automation news, nRichDx and Hamilton announced an end‑to‑end automated liquid biopsy sample‑prep workflow integrating nRichDx’s Revolution Plus extraction with Hamilton’s Microlab STAR to automate high‑volume cfDNA and CTC isolation. The integrated solution targets reproducibility and throughput for translational and clinical labs. These financing and automation developments signal growing investor and customer appetite for scaled manufacturing and automated sample‑handling solutions that reduce bottlenecks in cell therapy and liquid biopsy pipelines, a precondition for broader commercialization of next‑generation biologics.